N. Germann

919 total citations
16 papers, 602 citations indexed

About

N. Germann is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, N. Germann has authored 16 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in N. Germann's work include Cancer Risks and Factors (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). N. Germann is often cited by papers focused on Cancer Risks and Factors (3 papers), Ovarian cancer diagnosis and treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). N. Germann collaborates with scholars based in France, Denmark and United Kingdom. N. Germann's co-authors include François Goldwasser, François Goffinet, François Blot, Bruno Raynard, Gérard Nitenberg, Agnès Laplanche, S. Antoun, Cyrille Tancrède, Christian Brun‐Buisson and Philippe Morice and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

N. Germann

16 papers receiving 585 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Germann France 10 255 226 198 139 90 16 602
Saloua Ladeb Tunisia 15 145 0.6× 95 0.4× 173 0.9× 63 0.5× 64 0.7× 55 688
Aaron Cumpston United States 17 199 0.8× 243 1.1× 51 0.3× 54 0.4× 44 0.5× 55 722
Mahendra Agraharkar United States 12 87 0.3× 52 0.2× 65 0.3× 40 0.3× 7 0.1× 35 512
Victor M. Aquino United States 16 417 1.6× 218 1.0× 46 0.2× 76 0.5× 213 2.4× 36 840
Ülker Koçak Türkiye 14 94 0.4× 92 0.4× 9 0.0× 100 0.7× 25 0.3× 67 580
Tarek Ben Othman Tunisia 11 80 0.3× 57 0.3× 171 0.9× 48 0.3× 13 0.1× 32 484
D Anaise United States 11 54 0.2× 46 0.2× 116 0.6× 109 0.8× 12 0.1× 58 531
Fu–Keung Li Hong Kong 13 34 0.1× 118 0.5× 94 0.5× 24 0.2× 10 0.1× 19 756
Annachiara Ferrari Italy 9 29 0.1× 166 0.7× 34 0.2× 59 0.4× 8 0.1× 24 384
Madelon van Agteren Netherlands 11 82 0.3× 83 0.4× 154 0.8× 69 0.5× 5 0.1× 24 607

Countries citing papers authored by N. Germann

Since Specialization
Citations

This map shows the geographic impact of N. Germann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Germann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Germann more than expected).

Fields of papers citing papers by N. Germann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Germann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Germann. The network helps show where N. Germann may publish in the future.

Co-authorship network of co-authors of N. Germann

This figure shows the co-authorship network connecting the top 25 collaborators of N. Germann. A scholar is included among the top collaborators of N. Germann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Germann. N. Germann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Escudier, Bernard, Sandrine Faivre, Eric Van Cutsem, et al.. (2017). A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Targeted Oncology. 12(5). 655–661. 21 indexed citations
3.
4.
Fizazi, Karim, Albertas Ulys, Lisa Sengeløv, et al.. (2016). A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.. Journal of Clinical Oncology. 34(2_suppl). 201–201. 1 indexed citations
5.
6.
Cacheux, Wulfran, et al.. (2008). An original administration of ifosfamide given once every other week: a clinical and pharmacological study. Anti-Cancer Drugs. 19(3). 295–302. 2 indexed citations
7.
Labourey, Jean-Luc, Didier Cupissol, G. Calais, et al.. (2007). Docetaxel Plus Gemcitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head And Neck. American Journal of Clinical Oncology. 30(3). 278–282. 15 indexed citations
8.
Germann, N., Christine Haie-Méder, Philippe Morice, et al.. (2005). Management and clinical outcomes of pregnant patients with invasive cervical cancer. Annals of Oncology. 16(3). 397–402. 69 indexed citations
9.
Taı̈eb, Julien, Thierry Lecomte, Pascal Artru, et al.. (2005). 5-FU/ folinic acid plus CPT-11 (FOLFIRI.3 regimen) in advanced pancreatic carcinoma (PC): results of an AGEO phase II study. Journal of Clinical Oncology. 23(16_suppl). 4116–4116. 1 indexed citations
10.
Germann, N., Saı̈k Urien, Marion S. Ratterree, et al.. (2004). Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide. Cancer Chemotherapy and Pharmacology. 55(2). 143–151. 11 indexed citations
11.
Germann, N., François Goffinet, & François Goldwasser. (2003). Anthracyclines during pregnancy: embryo–fetal outcome in 160 patients. Annals of Oncology. 15(1). 146–150. 107 indexed citations
12.
Germann, N., Marine Gross‐Goupil, Ernesto Wasserman, et al.. (2002). The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of α-fetoprotein or β-human chorionic gonadotrophin: report of two cases. Annals of Oncology. 13(4). 632–636. 9 indexed citations
13.
Morice, Philippe, S. Camatte, Patricia Pautier, et al.. (2002). [Gynecological cancers and pregnancy: the point of view of the oncology gynecologist].. PubMed. 89(9). 765–71. 8 indexed citations
14.
Blot, François, Agnès Laplanche, Bruno Raynard, et al.. (2000). Accuracy of totally implanted ports, tunnelled, single- and multiple-lumen central venous catheters for measurement of central venous pressure. Intensive Care Medicine. 26(12). 1837–1842. 10 indexed citations
15.
Germann, N., S. Brienza, Jean‐François Emile, et al.. (1999). Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Annals of Oncology. 10(3). 351–354. 44 indexed citations
16.
Blot, François, Gérard Nitenberg, Bruno Raynard, et al.. (1999). Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. The Lancet. 354(9184). 1071–1077. 275 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saloua Ladeb Breakdown of academic impact, for papers by Aaron Cumpston Breakdown of academic impact, for papers by Mahendra Agraharkar Breakdown of academic impact, for papers by Victor M. Aquino Breakdown of academic impact, for papers by Ülker Koçak Breakdown of academic impact, for papers by Tarek Ben Othman Breakdown of academic impact, for papers by D Anaise Breakdown of academic impact, for papers by Fu–Keung Li Breakdown of academic impact, for papers by Annachiara Ferrari Breakdown of academic impact, for papers by Madelon van Agteren
Rankless by CCL
2026